Cargando…
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. T...
Autores principales: | Merseburger, Axel S., Hupe, Marie C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939158/ https://www.ncbi.nlm.nih.gov/pubmed/27246172 http://dx.doi.org/10.1007/s12325-016-0351-4 |
Ejemplares similares
-
Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016) -
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014) -
An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011) -
Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update
por: Hara, Noboru
Publicado: (2012) -
Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
por: Bagrodia, Aditya, et al.
Publicado: (2009)